No regulatory pathway exists for patient-specific bioprinted organs ('batch of one')

Bioprinted organs are inherently patient-specific: each construct uses the patient's own cells, is printed to their anatomy, and cannot be batch-tested like a pharmaceutical. So what? Traditional FDA/EMA regulatory frameworks require batch testing, statistical quality control over multiple units, and standardized manufacturing processes -- none of which apply to a one-off, patient-specific construct. So what? Companies developing bioprinted tissues cannot submit through existing device, biologic, or drug pathways because bioprinted constructs are combination products (cells + scaffold + growth factors) that straddle multiple regulatory categories simultaneously. So what? Without a clear regulatory pathway, no investor will fund the $50-100M needed to bring a bioprinted organ through clinical trials, and no hospital IRB can approve implantation. The technology sits in a regulatory no-man's-land. Why does this persist? Regulators require destructive testing to characterize a product's biomechanical and biological properties -- but destructive testing destroys the very construct intended for the patient. You cannot test the organ you plan to implant. Non-destructive quality assurance methods for living, 3D, heterogeneous tissue constructs do not exist at the fidelity needed for clinical confidence.